OverviewSuggest Edit

Nightstar Therapeutics is a clinical-stage gene therapy company, focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. The Company’s lead product candidate includes NSR-REP1 that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia. It is also developing NSR-RPGR that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, which is in preclinical development for the treatment of Best vitelliform macular dystrophy.

... Show more
TypePublic
Founded2013
HQLondon, GB
Websitenightstarx.com

Latest Updates

Employees (est.) (Feb 2019)27
Share Price (Dec 2018)$11.6 (-3%)

Nightstar Therapeutics Office Locations

Nightstar Therapeutics has offices in London and Lexington
London, GB (HQ)
215 Euston Rd
Lexington, US
100, 81 Hartwell Ave
Show all (2)
Report incorrect company information

Nightstar Therapeutics Financials and Metrics

Nightstar Therapeutics Revenue

USD

Net income (H1, 2017)

(7.7m)

EBIT (H1, 2017)

(7.7m)

Market capitalization (14-Dec-2018)

389.8m

Closing stock price (14-Dec-2018)

11.6

Cash (30-Jun-2017)

69.6m
Nightstar Therapeutics's current market capitalization is $389.8 m.
Annual
USDFY, 2015FY, 2016

General and administrative expense

2.1m2.1m

R&D expense

7.2m10.2m

Operating expense total

9.3m12.2m

EBIT

(9.3m)(12.2m)
Half Year
USDH1, 2016H1, 2017

General and administrative expense

812.0k1.4m

R&D expense

5.1m6.3m

Operating expense total

5.9m7.7m

EBIT

(5.9m)(7.7m)
Annual
USDFY, 2015FY, 2016

Cash

10.7m10.1m

Prepaid Expenses

3.1m4.1m

Current Assets

13.8m14.2m

PP&E

253.0k363.0k
Half Year
USDH1, 2017

Cash

69.6m

Prepaid Expenses

6.5m

Current Assets

76.1m

PP&E

342.0k
Annual
USDFY, 2015FY, 2016

Net Income

(13.6m)(12.2m)

Depreciation and Amortization

40.0k138.0k

Accounts Payable

384.0k419.0k

Cash From Operating Activities

(9.7m)(10.1m)
Half Year
USDH1, 2016H1, 2017

Net Income

(5.9m)(7.7m)

Depreciation and Amortization

51.0k95.0k

Accounts Payable

91.0k1.7m

Cash From Operating Activities

(5.9m)(5.7m)
USDY, 2017

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Nightstar Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Nightstar Therapeutics News and Updates

Nightstar Therapeutics to Participate in Multiple Conferences in November

WALTHAM, Mass. and LONDON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company will participate in the following investor conferences in Novembe…

Nightstar Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights

Regenerative Medicine Advanced Therapy (RMAT) Designation received in June 2018 for NSR-REP1 in Choroideremia
Report incorrect company information

Nightstar Therapeutics Blogs

Elemer Piros, Ph.D.

Elemer Piros, Ph.D. Jonathan.Lorin… Thu, 10/11/2018 - 09:15 Elemer Piros, Ph.D. Cantor Fitzgerald

Nightstar Therapeutics to Present at Chardan Genetic Medicines Conference

Nightstar Therapeutics to Present at Chardan Genetic Medicines Conference Content Import Thu, 10/04/2018 - 06:08 Nightstar Therapeutics to Present at Chardan Genetic Medicines Conference October 4, 2018 This release is a backfill from a News Wire General …

Nightstar Announces Pricing of Public Offering

WALTHAM, Mass. and LONDON , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced the pricing of an underwritten public offering of 4,000,000 American Depositary

Nightstar Therapeutics Company Life and Culture

Report incorrect company information

Nightstar Therapeutics Frequently Asked Questions

  • When was Nightstar Therapeutics founded?

    Nightstar Therapeutics was founded in 2013.

  • How many employees does Nightstar Therapeutics have?

    Nightstar Therapeutics has 27 employees.

  • Who are Nightstar Therapeutics competitors?

    Competitors of Nightstar Therapeutics include Ultragenyx Pharmaceutical, Aevi Genomic Medicine and Vical.

  • Where is Nightstar Therapeutics headquarters?

    Nightstar Therapeutics headquarters is located at 215 Euston Rd, London.

  • Where are Nightstar Therapeutics offices?

    Nightstar Therapeutics has offices in London and Lexington.

  • How many offices does Nightstar Therapeutics have?

    Nightstar Therapeutics has 2 offices.